International Journal of Colorectal Disease

, Volume 30, Issue 1, pp 1–10 | Cite as

Advances in malignant peritoneal mesothelioma

  • Shoubo Cao
  • Shi Jin
  • Jingyan Cao
  • Jing Shen
  • Jing Hu
  • Dehai Che
  • Bo Pan
  • Jiawen Zhang
  • Xiaoxi He
  • Dian Ding
  • Feifei Gu
  • Yan YuEmail author



Malignant mesothelioma is a rare, insidious, and aggressive tumor arising from the mesothelial surface of pleural and peritoneal cavities, the pericardium, or the tunica vaginalis, with an increasing incidence worldwide, high misdiagnosis rate, and overall negative prognosis. A total of 20 % of all cases is peritoneum in origin.


The present study is a review of literatures focusing on the advances in epidemiology, clinical presentations, radiological features, diagnosis, misdiagnosis, management, and prognostic factors of malignant peritoneal mesothelioma (MPM) occurred in the past decades.


Asbestos, SV40, and radiation exposures have been demonstrated to be correlated with the pathogenesis of MPM. The main presentations are abdominal distension and pain. Computed tomography (CT), magnetic resonance imaging (MRI), and positron-emission tomography (PET) play an important role in the preoperative imaging and staging. Definitive diagnosis is made on the basis of immunohistochemistry. Prognostic factors have been identified and verified. Negative indicators include advanced age, male gender, poor performance status, non-epithelial histology, and absence of surgery. The management of MPM has evolved from single chemotherapy to multimodality treatment of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC), chemotherapy, radiotherapy, and immunotherapy. Promising results have been achieved after a combined treatment of CRS and HIPEC, with an elevated median survival time of 29.5–92 months and a 5-year survival rate of 39–63 %.


CRS and HIPEC represent the standard treatment strategy for selected patients with MPM, and patients with unresectable tumors can benefit from the combined treatment of chemotherapy, radiotherapy, and immunotherapy.


MPM CRS HIPEC Diagnosis Management 



This work was supported by Wujieping Foundation (No. 320.6750.12204), Young People Research Fund for the grant National Natural Scientific Foundation of China (No. 81201828), Young People Foundation of Heilongjiang Provincial of China (No. QC2012C013), National Natural Scientific Foundation of China (No. 81101758), Health Department of Heilongjiang Provincial of China (No: 2011-124) and Harbin Medical University Cancer Hospital major project Foundation (No: JJZ-2010-01).

Conflict of interest



  1. 1.
    Sharma H, Bell I, Schofield J et al (2011) Primary peritoneal mesothelioma: case series and literature review. Clin Res Hepathol Gastroenterol 35:55–59CrossRefGoogle Scholar
  2. 2.
    Carbone M, Ly BH, Dodson RF et al (2012) Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol 227:44–58PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Moore AJ, Parker RJ, Wiggins J (2008) Malignant mesothelioma. Orphanet J Rare Dis 3:34PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Robinson BW, Lake RA (2005) Advances in malignant mesothelioma. N Engl J Med 353:1591–1603PubMedCrossRefGoogle Scholar
  5. 5.
    Roe OD, Creaney J, Lundgren S et al (2008) Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study. Lung Cancer 61:235–243PubMedCrossRefGoogle Scholar
  6. 6.
    Garcia-Carbonero R, Paz-Ares L (2006) Systemic chemotherapy in the management of malignant peritoneal mesothelioma. Eur J Surg Oncol 32:676–681PubMedCrossRefGoogle Scholar
  7. 7.
    De Pangher Manzini V (2005) Malignant peritoneal mesothelioma. Tumori 91:1–5PubMedGoogle Scholar
  8. 8.
    Wagner JC, Sleegs CA, Marchand P (1960) Diffuse pleural mesothelioma. Br J Ind Med 17:260–271PubMedCentralPubMedGoogle Scholar
  9. 9.
    Tan GH, Cheung M, Chanyaputhipong J et al (2013) Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma. Ann Acad Med Singapore 42:291–296PubMedGoogle Scholar
  10. 10.
    Mirarabshahii P, Pillai K, Chua TC et al (2012) Diffuse malignant peritoneal mesothelioma—an update on treatment. Cancer Treat Rev 38:605–612PubMedCrossRefGoogle Scholar
  11. 11.
    Magge D, Zenati MS, Austin F et al (2014) Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol 21:1159–1165PubMedCrossRefGoogle Scholar
  12. 12.
    Baratti D, Kusamura S, Cabras AD et al (2013) Diffuse malignant peritoneal mesothelioma: long-term survival with complete cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Cancer 49:3140–3148PubMedCrossRefGoogle Scholar
  13. 13.
    Chua TC, Yan TD, Morris DL (2009) Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience. J Surg Oncol 99:109–113PubMedCrossRefGoogle Scholar
  14. 14.
    Yan TD, Deraco M, Baratti D et al (2009) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol 27:6237–6242PubMedCrossRefGoogle Scholar
  15. 15.
    Goslin B, Sevak S, Siripong A et al (2012) Outcomes of cytoreduction with hyperthermic intraperitoneal chemotherapy: our experience at a midwest community hospital. Am J Surg 203:383–386PubMedCrossRefGoogle Scholar
  16. 16.
    Miller J, Wynn H (1908) A malignant tumor arising from the endothelium of the peritoneum and producing a mucoid ascitic fluid. J Pathol Bacteriol 12:267CrossRefGoogle Scholar
  17. 17.
    Marinaccio A, Montanaro F, Mastrantonio M et al (2005) Predictions of mortality from pleural mesothelioma in Italy: a model based on asbestos consumption figures supports results from age-period-cohort models. Int J Cancer 115:142–147PubMedCrossRefGoogle Scholar
  18. 18.
    Gogou E, Kerenidi T, Chamos V et al (2009) Mesothelioma mortality in Greece from 1983 to 2003. Int J Clin Pract 63:944–948PubMedCrossRefGoogle Scholar
  19. 19.
    Myojin T, Azuma K, Okumura J et al (2012) Future trends of mesothelioma mortality in Japan based on a risk function. Ind Health 50:197–204PubMedCrossRefGoogle Scholar
  20. 20.
    Schonfeld SJ, McCormack V, Rutherford MJ et al (2014) Regional variations in German mesothelioma mortality rates: 2000–2010. Cancer Causes Control 25:615–624PubMedCrossRefGoogle Scholar
  21. 21.
    Hodgson JT, McElvenny DM, Darnton AJ et al (2005) The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer 92:587–593PubMedCentralPubMedGoogle Scholar
  22. 22.
    Pitarque S, Clèries R, Martínez JM et al (2008) Mesothelioma mortality in men: trends during 1977–2001 and projections for 2002–2016 in Spain. Occup Environ Med 65:279–282PubMedCrossRefGoogle Scholar
  23. 23.
    Banaei A, Auvert B, Goldberg M et al (2000) Future trends in mortality of French men from mesothelioma. Occup Environ Med 57:488–494PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Leigh J, Davidson P, Hendrie L et al (2002) Malignant mesothelioma in Australia, 1945–2000. Am J Ind Med 41:188–201PubMedCrossRefGoogle Scholar
  25. 25.
    Price B, Ware A (2004) Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003. Am J Epidemiol 159:107–112PubMedCrossRefGoogle Scholar
  26. 26.
    Naka H, Naka A (1984) Clinicopathological study on 100 Japanese patients with peritoneal mesothelioma in Japan. Gan No Rinsho 30:1–10PubMedGoogle Scholar
  27. 27.
    Metintas M, Hillerdal G, Metintas S (1999) Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. Eur Respir J 13:523–526PubMedCrossRefGoogle Scholar
  28. 28.
    Stey C, Landolt-Weber U, Vetter W et al (1995) Malignant peritoneal mesothelioma after Thorotrast exposure. Am J Clin Oncol 18:313–317PubMedCrossRefGoogle Scholar
  29. 29.
    Weissmann LB, Corson JM, Neugut AI et al (1996) Malignant mesothelioma following treatment for Hodgkin’s disease. J Clin Oncol 14:2098–2100PubMedGoogle Scholar
  30. 30.
    Shivapurkar N, Wiethege T, Wistuba II et al (1999) Presence of simian virus 40 sequences in malignant mesotheliomas and mesothelial cell proliferations. J Cell Biochem 76:181–188PubMedCrossRefGoogle Scholar
  31. 31.
    Acherman YI, Welch LS, Bromley CM et al (2003) Clinical presentation of peritoneal mesothelioma. Tumori 89:269–273PubMedGoogle Scholar
  32. 32.
    Manzini Vde P, Recchia L, Cafferata M et al (2010) Malignant peritoneal mesothelioma: a multicenter study on 81 cases. Ann Oncol 21:348–353PubMedCrossRefGoogle Scholar
  33. 33.
    Cao SB, Jin S, Cao JY et al (2014) Colonic invasion induced by malignant peritoneal mesothelioma. Int J Colorectal Dis 29:891–892PubMedCrossRefGoogle Scholar
  34. 34.
    Munkholm-Larsen S, Cao CQ, Yan TD (2009) Malignant peritoneal mesothelioma. World J Gastrointest Surg 1:38–48PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Tabata C, Kanemura S, Tabata R et al (2013) Serum HMGB1 as a diagnostic marker for malignant peritoneal mesothelioma. J Clin Gastroenterol 47:684–688PubMedCrossRefGoogle Scholar
  36. 36.
    Park JY, Kim KW, Kwon HJ et al (2008) Peritoneal mesotheliomas: clinicopathologic features, CT findings, and differential diagnosis. AJR Am J Roentgenol 191:814–825PubMedCrossRefGoogle Scholar
  37. 37.
    Nagata S, Tomoeda M, Kubo C et al (2011) Malignant mesothelioma of the peritoneum invading the liver and mimicking metastatic carcinoma: a case report. Pathol Res Pract 207:395–398PubMedCrossRefGoogle Scholar
  38. 38.
    Daskalogiannaki M, Prassopoulos P, Raissaki M et al (2000) Malignant peritoneal mesothelioma presenting with respiratory symptoms. Eur Radiol 10:814–816PubMedCrossRefGoogle Scholar
  39. 39.
    Heatley MK (2004) Sister Mary Joseph’s nodule in malignant mesothelioma. Histopathology 45:299–300PubMedCrossRefGoogle Scholar
  40. 40.
    Haliloglu M, Hoffer FA, Fletcher BD (2000) Malignant peritoneal mesothelioma in two pediatric patients: MR imaging findings. Pediatr Radiol 30:251–255PubMedCrossRefGoogle Scholar
  41. 41.
    Yamamuro M, Gerbaudo VH, Gill RR et al (2007) Morphologic and functional imaging of malignant pleural mesothelioma. Eur J Radiol 64:356–366PubMedCrossRefGoogle Scholar
  42. 42.
    Cao Q, Lu M, Heath J et al (2012) 18F-FDG PET/CT in a recurrent diffuse malignant peritoneal mesothelioma. Clin Nucl Med 37:492–494PubMedCrossRefGoogle Scholar
  43. 43.
    Iversen LH, Rasmussen PC, Laurberg S (2013) Value of laparoscopy before cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis. Br J Surg 100:285–292PubMedCrossRefGoogle Scholar
  44. 44.
    Wang J, Gao L, Tang S et al (2013) A retrospective analysis on the diagnostic value of ultrasound-guided percutaneous biopsy for peritoneal lesions. World J Surg Oncol 11:251PubMedCentralPubMedCrossRefGoogle Scholar
  45. 45.
    Marchevsky AM (2008) Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Arch Pathol Lab Med 132:397–401PubMedGoogle Scholar
  46. 46.
    Suster S, Moran CA (2006) Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma. Adv Anat Pathol 13:316–329PubMedCrossRefGoogle Scholar
  47. 47.
    Taşkın S, Gümüş Y, Kiremitçi S et al (2012) Malignant peritoneal mesothelioma presented as peritoneal adenocarcinoma or primary ovarian cancer: case series and review of the clinical and immunohistochemical features. Int J Clin Exp Pathol 5:472–478PubMedCentralPubMedGoogle Scholar
  48. 48.
    Laury AR, Hornick JL, Perets R et al (2010) PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma. Am J Surg Pathol 34:627–635PubMedGoogle Scholar
  49. 49.
    Krasuski P, Poniecka A, Gal E (2002) The diagnostic challenge of peritoneal mesothelioma. Arch Gynecol Obstet 266:130–132PubMedCrossRefGoogle Scholar
  50. 50.
    Chen LY, Huang LX, Wang J et al (2011) Malignant peritoneal mesothelioma presenting with persistent high fever. J Zhejiang Univ Sci B 12:381–384PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Rogoff EE, Hilaris BS, Huvos AG (1973) Long-term survival in patients with malignant peritoneal mesothelioma treated with irradiation. Cancer 32:656–664PubMedCrossRefGoogle Scholar
  52. 52.
    Cain J, Nori D, Huvos A et al (1983) The role of radioactive colloids in malignant peritoneal mesothelioma. Gynecol Oncol 16:263–274PubMedCrossRefGoogle Scholar
  53. 53.
    Lederman GS, Recht A, Herman T et al (1987) Long-term survival in peritoneal mesothelioma. The role of radiotherapy and combined modality treatment. Cancer 59:1882–1886PubMedCrossRefGoogle Scholar
  54. 54.
    Hesdorffer ME, Chabot JA, Keohan ML et al (2008) Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol 31:49–54PubMedCrossRefGoogle Scholar
  55. 55.
    Takeuchi K, Fujimoto M, Tsujino T et al (2007) Impressive remission of locally advanced malignant peritoneal mesothelioma treated with combination of radiotherapy and intraperitoneal paclitaxel. Eur J Gynaecol Oncol 28:322–323PubMedGoogle Scholar
  56. 56.
    Turner K, Varghese S, Alexander HR Jr (2012) Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma. J Natl Compr Cancer Netw 10:49–57Google Scholar
  57. 57.
    O’Brien ME, Watkins D, Ryan C et al (2006) A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol 17:270–275PubMedCrossRefGoogle Scholar
  58. 58.
    Simon GR, Verschraegen CF, Jänne PA et al (2008) Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial. J Clin Oncol 26:3567–3572PubMedCrossRefGoogle Scholar
  59. 59.
    Verschraegen CF (2001) Intracavitary therapies for mesothelioma. Curr Treat Options Oncol 2:385–394PubMedCrossRefGoogle Scholar
  60. 60.
    Leinwand JC, Zhao B, Guo X et al (2013) Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy. Ann Surg Oncol 20:S553–S559PubMedCrossRefGoogle Scholar
  61. 61.
    Cameron RB, Hou D (2013) Intraoperative hyperthermic chemotherapy perfusion for malignant pleural mesothelioma: an in vitro evaluation. J Thorac Cardiovasc Surg 145:496–504PubMedCrossRefGoogle Scholar
  62. 62.
    Sebbag G, Yan H, Shmookler BM et al (2000) Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg 87:1587–1593PubMedCrossRefGoogle Scholar
  63. 63.
    Deraco M, Nonaka D, Baratti D et al (2006) Prognostic analysis of clinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion. Ann Surg Oncol 13:229–237PubMedCrossRefGoogle Scholar
  64. 64.
    Teo MC, Tan GH, Tham CK et al (2013) Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in Asian patients: 100 consecutive patients in a single institution. Ann Surg Oncol 20:2968–2974PubMedCrossRefGoogle Scholar
  65. 65.
    Alexander HR Jr, Bartlett DL, Pingpank JF et al (2013) Treatment factors associated with long-term survival following cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery 153:779–786PubMedCentralPubMedCrossRefGoogle Scholar
  66. 66.
    Haslinger M, Francescutti V, Attwood K et al (2013) A contemporary analysis of morbidity and outcomes in cytoreduction/hyperthermic intraperitoneal chemoperfusion. Cancer Med 2:334–342PubMedCentralPubMedCrossRefGoogle Scholar
  67. 67.
    Levine EA, Stewart JH 4th, Shen P et al (2014) Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg 218:573–587PubMedCrossRefGoogle Scholar
  68. 68.
    Feldman AL, Libutti SK, Pingpank JF et al (2003) Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21:4560–4567PubMedCrossRefGoogle Scholar
  69. 69.
    Alexander HR Jr (2010) Surgical treatment of malignant peritoneal mesothelioma: past, present, and future. Ann Surg Oncol 17:21–22PubMedCentralPubMedCrossRefGoogle Scholar
  70. 70.
    Los G, Smals OA, van Vugt MJ et al (1992) A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 52:1252–1258PubMedGoogle Scholar
  71. 71.
    Randle RW, Swett KR, Swords DS et al (2014) Efficacy of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in the management of malignant ascites. Ann Surg Oncol 21:1474–1479PubMedCentralPubMedCrossRefGoogle Scholar
  72. 72.
    Votanopoulos KI, Ihemelandu C, Shen P et al (2012) Outcomes of repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. J Am Coll Surg 215:412–417PubMedCentralPubMedCrossRefGoogle Scholar
  73. 73.
    Chua TC, Quinn LE, Zhao J et al (2013) Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent peritoneal metastases. J Surg Oncol 108:81–88PubMedCrossRefGoogle Scholar
  74. 74.
    Soulié P, Ruffié P, Trandafir L et al (1996) Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 14:878–885PubMedGoogle Scholar
  75. 75.
    Bielefeldt-Ohmann H, Marzo AL, Himbeck RP et al (1995) Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon alpha immunotherapy. Cancer Immunol Immunother 40:241–250PubMedCrossRefGoogle Scholar
  76. 76.
    Tani M, Tanimura H, Yamaue H et al (1998) Successful immunochemotherapy for patients with malignant mesothelioma: report of two cases. Surg Today 28:647–651PubMedCrossRefGoogle Scholar
  77. 77.
    Hegmans JP, Hemmes A, Aerts JG et al (2005) Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells. Am J Respir Crit Care Med 171:1168–1177PubMedCrossRefGoogle Scholar
  78. 78.
    Ho M, Feng M, Fisher RJ et al (2011) A novel high-affinity human monoclonal antibody to mesothelin. Int J Cancer 128:2020–2030PubMedCentralPubMedCrossRefGoogle Scholar
  79. 79.
    Govindan R, Kratzke RA, Herndon JE 2nd et al (2005) Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clin Cancer Res 11:2300–2304PubMedCrossRefGoogle Scholar
  80. 80.
    Yan TD, Brun EA, Cerruto CA et al (2007) Prognostic indicators for patients undergoing cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 14:41–49PubMedCrossRefGoogle Scholar
  81. 81.
    Cao C, Yan TD, Deraco M et al (2012) Importance of gender in diffuse malignant peritoneal mesothelioma. Ann Oncol 23:1494–1498PubMedCrossRefGoogle Scholar
  82. 82.
    Wolf AS, Richards WG, Tilleman TR et al (2010) Characteristics of malignant pleural mesothelioma in women. Ann Thorac Surg 90:949–956PubMedCrossRefGoogle Scholar
  83. 83.
    Pillai K, Pourgholami MH, Chua TC et al (2013) Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma. J Cancer Res Clin Oncol 139:987–994PubMedCrossRefGoogle Scholar
  84. 84.
    Yan TD, Yoo D, Sugarbaker PH (2006) Significance of lymph node metastasis in patients with malignant peritoneal mesothelioma. Eur J Surg Oncol 32:948–953PubMedCrossRefGoogle Scholar
  85. 85.
    Baratti D, Kusamura S, Cabras AD et al (2010) Lymph node metastases in diffuse malignant peritoneal mesothelioma. Ann Surg Oncol 17:45–53PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Shoubo Cao
    • 1
  • Shi Jin
    • 1
  • Jingyan Cao
    • 1
  • Jing Shen
    • 1
  • Jing Hu
    • 1
  • Dehai Che
    • 1
  • Bo Pan
    • 1
  • Jiawen Zhang
    • 1
  • Xiaoxi He
    • 1
  • Dian Ding
    • 1
  • Feifei Gu
    • 1
  • Yan Yu
    • 1
    Email author
  1. 1.Department of Medical OncologyHarbin Medical University Cancer HospitalHarbinChina

Personalised recommendations